Get In Touch

Alzheimer’s disease is an irreversible neural disease that progresses with age. Alzheimer’s disease is characterized by degeneration of brain cells i.e., neurons, which leads to loss of memory and other important functions controlled by the central nervous system (CNS). Symptoms of the disease are memory loss and mild confusion, often termed as dementia. These symptoms are visible in patients aged 50 to 60 years. Alzheimer’s is considered to be caused by a combination of genetic, environmental, and lifestyle induced factors. Alzheimer’s disease is mostly diagnosed among the patients who are having symptoms similar to Alzheimer’s disease such as memory loss, dementia, etc., it is often post-onset of the disease. Till recently, there were no tests or tools to pre-diagnose this disease or to check the susceptibility of a patient for Alzheimer’s disease.

Standard diagnosis protocol for diagnosing Alzheimer’s disease was limited to subjective tests on memory, problem solving, behavior, and personality. Correlation of past medical problems and family history of Alzheimer’s disease are also taken into consideration for diagnosis. Physicians also perform various imaging tests such as computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET). These tests may be repeated to confirm the disease; however, Alzheimer’s disease can be conclusively confirmed only after death of a patient through autopsy of the brain tissue and linking it with clinical findings. In April 2017, the U.S. FDA approved 23andMe, Inc. to offer a genetic test for pre-diagnosis of Alzheimer’s disease directly to customers. Similarly, in February 2018, researchers at Japan-based Shimadzu Corporation announced that they have developed blood test for prediction of onset of Alzheimer’s disease based on detection of amyloid beta (Aβ) deposits. Technical advancements in diagnostic tests and tools for Alzheimer’s disease are projected to propel the global Alzheimer’s disease biomarkers market. However, accessibility of these tests and tools and estimated high cost of procedures are likely to hamper the market during the forecast period.

Alzheimer’s disease can be diagnosed using specific biomarkers such as peptides and genes. These biomarkers play an important role in predictive and confirmatory diagnosis of Alzheimer’s disease. The global Alzheimer’s disease biomarkers market can be segmented based on type of biomarker, detection technique, end-user, and region. In terms of type of biomarker, the market can be classified into peptide-based, gene-based, imaging biomarkers, and others. The peptide-based segment can be categorized into beta amyloid-based, tau protein-based, and others. The gene-based segment can be divided into apolipoprotein E-based, amyloid precursor protein & presenilin-based, and others. Among these, gene-based biomarkers are likely to be more accurate. Increase in demand for molecular diagnostics such as PCR is projected to spur adoption of these biomarkers. Based on detection technique, the global Alzheimer’s disease biomarkers market can be segmented into polymerase chain reaction (PCR), enzyme linked immunoassay (ELISA), and radiology imaging such as CT, MRI, and PET scan. Major end-users of Alzheimer’s disease biomarkers are hospitals & clinics, independent diagnostic laboratories, and others.

In terms of region, the global Alzheimer’s disease biomarkers market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. High adoption of technically advanced diagnostic tools and better reimbursement support in the U.S. are projected to boost the Alzheimer’s disease biomarkers market in North America during the forecast period. A report published by Alzheimer’s Disease International stated that an estimated 10.5 million people in Europe and 22.9 million in Asia Pacific were reported to have Alzheimer’s disease in 2015. High prevalence of Alzheimer’s disease in these regions is anticipated to propel the Alzheimer’s disease biomarkers market in Europe and Asia Pacific during the forecast period. However, limited access, lack of awareness, and estimated high cost of diagnostic procedures are expected to restrain the market in Asia Pacific.
Major players operating in the global Alzheimer’s disease biomarkers market are NanoSomix, Inc., Fujirebio, Imagilys SPRL, Merck KGaA, Enzo Life Sciences, Inc., Cell Signaling Technology, Inc., QIAGEN, 23andMe, Inc., AnaSpec, Inc., and Thermo Fisher Scientific, and others.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Alzheimers Disease Biomarkers Market

Pre Book